Gilead - No Statistical Power" - Fake news.
Fake news, Og to pasienter doede uten og ha vaert saa syke at de trengte ventilator. Samme medisin ble benyttet i Kina uten effekt.
Gilead Pours Cold Water On Report That Sent Market Soaring: "Anecdotal Reports With No Statistical Power".
"We understand the urgent need for a Covid-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir. The totality of the data need to be analysed in order to draw any conclusions from the trial."
"Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19.
zerohedge.com/health/gilead-pours-cold-water-report-sent-market-soaring-anecdotal-reports-no-statistical-power
Gilead Pours Cold Water On Report That Sent Market Soaring: "Anecdotal Reports With No Statistical Power".
"We understand the urgent need for a Covid-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir. The totality of the data need to be analysed in order to draw any conclusions from the trial."
"Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19.
zerohedge.com/health/gilead-pours-cold-water-report-sent-market-soaring-anecdotal-reports-no-statistical-power
Redigert 21.01.2021 kl 09:34
Du må logge inn for å svare
tuja
17.04.2020 kl 09:16
865
Og børsene hopper flere prosent på "fake news". Slik har verden blitt. Hvem blir Svarte Per denne gangen?
Redigert 21.01.2021 kl 07:20
Du må logge inn for å svare
tuja
17.04.2020 kl 09:38
837
Fra selskapet:
RTRS] - GILEAD - ANECDOTAL REPORTS DO NOT PROVIDE STATISTICAL POWER NECESSARY TO DETERMINE SAFETY, EFFICACY PROFILE OF REMDESIVIR AS TREATMENT FOR COVID-19
RTRS] - GILEAD - ANECDOTAL REPORTS DO NOT PROVIDE STATISTICAL POWER NECESSARY TO DETERMINE SAFETY, EFFICACY PROFILE OF REMDESIVIR AS TREATMENT FOR COVID-19
Redigert 21.01.2021 kl 07:20
Du må logge inn for å svare
tuja
17.04.2020 kl 09:42
826
https://www.ft.com/content/c0b7a2a1-e91e-44ef-9a96-55250cbbbaff?list=intlhomepage
The University of Chicago Medicine added that the partial data was by definition incomplete. “In this case, information from an internal forum for research colleagues concerning work in progress was released without authorisation,” it said. “Drawing any conclusions at this point is premature and scientifically unsound.”
The University of Chicago Medicine added that the partial data was by definition incomplete. “In this case, information from an internal forum for research colleagues concerning work in progress was released without authorisation,” it said. “Drawing any conclusions at this point is premature and scientifically unsound.”
Redigert 21.01.2021 kl 07:20
Du må logge inn for å svare
tuja
17.04.2020 kl 10:59
790
Wall Street analysts question investor excitement over virus drug
Biotech analysts on Wall Street have warned against over-reacting to hopes for a new coronavirus drug that could ease the pandemic.
A report in the medical press has suggested a coronavirus drug called 'remdesivir' developed by US pharma group Gilead had shown positive results in a clinical trial, sending Wall Street futures sharply higher.
Jefferies equity analysts said the excitement was "overdone in the near term", and highlighted that the findings do not come from the later stages of clinical research.
We appreciate that the broader market is in a risk-on and glass-half-full environment and investors are looking for a good story.
Healthcare analysts at Evercore said:
Did remdesivir just “solve” Covid? No.
While "cautiously optimistic", the bank's head of large cap therapeutics research Umer Raffat highlighted challenges interpreting the data and that the trial excluded patients who needed mechanical ventilation.
Thomas Lee at research boutique Fundstrat said any treatment could be as important as the longed-for vaccine against coronavirus. But he had a warning over the market's response:
[The virus] has compressed news/economic/financial cycles from months to days. What was normally 12 months of market moves is now happening in weeks....Financial markets are now starting to communicate a narrative that seems completely out of sync with what we know lays ahead.
Biotech analysts on Wall Street have warned against over-reacting to hopes for a new coronavirus drug that could ease the pandemic.
A report in the medical press has suggested a coronavirus drug called 'remdesivir' developed by US pharma group Gilead had shown positive results in a clinical trial, sending Wall Street futures sharply higher.
Jefferies equity analysts said the excitement was "overdone in the near term", and highlighted that the findings do not come from the later stages of clinical research.
We appreciate that the broader market is in a risk-on and glass-half-full environment and investors are looking for a good story.
Healthcare analysts at Evercore said:
Did remdesivir just “solve” Covid? No.
While "cautiously optimistic", the bank's head of large cap therapeutics research Umer Raffat highlighted challenges interpreting the data and that the trial excluded patients who needed mechanical ventilation.
Thomas Lee at research boutique Fundstrat said any treatment could be as important as the longed-for vaccine against coronavirus. But he had a warning over the market's response:
[The virus] has compressed news/economic/financial cycles from months to days. What was normally 12 months of market moves is now happening in weeks....Financial markets are now starting to communicate a narrative that seems completely out of sync with what we know lays ahead.
Redigert 21.01.2021 kl 07:20
Du må logge inn for å svare